Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Ivabradine
Actavis Group PTC ehf
C01EB; C01EB17
Ivabradine
7.5 milligram(s)
Film-coated tablet
Product subject to prescription which may be renewed (B)
Other cardiac preparations; ivabradine
Authorised
2017-08-11
1 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT IVABRADINE 5 MG FILM-COATED TABLETS IVABRADINE 7.5 MG FILM-COATED TABLETS ivabradine READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Ivabradine is and what it is used for 2. What you need to know before you take Ivabradine 3. How to take Ivabradine 4. Possible side effects 5 How to store Ivabradine 6. Contents of the pack and other information 1. WHAT IVABRADINE IS AND WHAT IT IS USED FOR Ivabradine contains the active substance ivabradine. Ivabradine is a heart medicine used to treat: - Symptomatic stable angina pectoris (which causes chest pain) in adult patients whose heart rate is over or equal to 70 beats per minute. It is used in adult patients who do not tolerate or cannot take heart medicines called beta-blockers. It is also used in combination with beta-blockers in adult patients whose condition is not fully controlled with a beta-blocker. - Chronic heart failure in adult patients whose heart rate is over or equal to 75 beats per minute. It is used in combination with standard therapy, including beta-blocker therapy or when beta-blockers are contraindicated or not tolerated. About stable angina pectoris (usually referred to as “angina”): Stable angina is a heart disease which happens when the heart does not receive enough oxygen. It usually appears between 40 and 50 years of age. The most common symptom of angina is chest pain or discomfort. Angina is more likely to happen when the heart beats faster in situations such as exercise, emo Read the complete document
Health Products Regulatory Authority 29 March 2019 CRN008V5D Page 1 of 13 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Ivabradine 7.5 mg Film-coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film‑coated tablet contains 7.5 mg ivabradine (as hydrochloride). Excipient with known effect: 80.48 mg lactose monohydrate For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet. White or almost white, triangular, biconvex, film-coated tablet, marked with “A267” on one side, tablet dimensions 7.5 x 7.2 mm. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Symptomatic treatment of chronic stable angina pectoris Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 bpm. Ivabradine is indicated: - in adults unable to tolerate or with a contra-indication to the use of beta-blockers - or in combination with beta‑blockers in patients inadequately controlled with an optimal beta‑blocker dose. Treatment of chronic heart failure Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta‑blocker therapy or when beta‑blocker therapy is contraindicated or not tolerated (see section 5.1). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology For the different doses, film‑coated tablets containing 5 mg and 7.5 mg ivabradine are available. _Symptomatic treatment of chronic stable angina pectoris_ It is recommended that the decision to initiate or titrate treatment takes place with the availability of serial heart rate measurements, ECG or ambulatory 24‑hour monitoring. The starting dose of ivabradine should not exceed 5 mg twice daily in patients aged below 75 years. After three to four weeks of treatment, if the patient is still symptomatic, if the initial dose is well tolerated and if res Read the complete document